Azurin, a copper-containing redox protein released by the pathogenic bacterium Pseudomonas aeruginosa, is highly cytotoxic to the human breast cancer cell line MCF-7, but is less cytotoxic toward p53-negative (MDA-MB-157) or nonfunctional p53 cell lines like MDD2 and MDA-MB-231. The purpose of this study was to investigate the underlying mechanism of the action of bacterial cupredoxin azurin in the regression of breast cancer and its potential chemotherapeutic efficacy. Azurin enters into the cytosol of MCF-7 cells and travels to the nucleus, enhancing the intracellular levels of p53 and Bax, thereby triggering the release of mitochondrial cytochrome c into the cytosol. This process activates the caspase cascade (including caspase-9 and caspase-7), thereby initiating the apoptotic process. Our results indicate that azurininduced cell death stimuli are amplified in the presence of p53. In vivo injection of azurin in immunodeficient mice harboring xenografted human breast cancer cells in the mammary fat pad leads to statistically significant regression (85%, P ¼ 0.0179, Kruskal-Wallis Test) of the tumor. In conclusion, azurin blocks breast cancer cell proliferation and induces apoptosis through the mitochondrial pathway both in vitro and in vivo, thereby suggesting a potential chemotherapeutic application of this bacterial cupredoxin for the treatment of breast cancer.
Introduction
With one million new cases in the world each year, breast cancer is the most common malignancy in women and constitutes 18% of all female cancers (Jemal et al., 2002) . Although there has been a slight decrease in mortality in breast cancer patients (Schiffman et al., 2002) , it is not uncommon for even early-stage breast cancer to metastasize. Therefore, novel therapeutic strategies are constantly being pursued (Bange et al., 2001) . Various candidates for breast cancer therapy include differentiating agents, angiogenesis inhibitors, vaccines, monoclonal antibodies, and approaches using dendritic cells (Tangri et al., 2001) . Recently, interest was rekindled in the old idea (Coley, 1911) of using live or attenuated pathogenic bacteria or their products in the treatment of cancer (Lamoureux et al., 1976; da Rocha et al., 2001; Chakrabarty, 2003; Sinha, 2003) .
The infection of tumor-bearing mice with live attenuated cells of Salmonella typhimurium has been reported to produce tumor regression (Pawelek et al., 1997) . A significant regression of subcutaneous tumors in mice was observed by combining anaerobic bacteria with various chemotherapeutic agents (Dang et al., 2001) . The antitumor activity of these pathogens has been attributed to the activation of an immune response against tumor antigens (Paglia and Guzman, 1998) , to the preferential growth of certain bacteria within the tumor (Sznol et al., 2000) , or to the inhibition of angiogenesis (Hunter et al., 2001) . However, live microorganisms with or without chemotherapeutic agents produce significant morbidity and mortality (Alexandroff et al., 1999; Dang et al., 2001) . Hence, studies are in progress to identify pure metabolites of microbial origin or any other components of the microbial cell that might have antitumor activity. One such example is the identification of secondary metabolites, epothilones A and B of the myxobacterium Sorangium cellulosum, which have shown both in vitro and in vivo cytotoxicity in various cancer cells, including MCF-7 cells (Chou et al., 1998; Altmann et al., 2000) .
We recently reported that azurin, a cupredoxin type of electron transfer agent elaborated by the bacterium Pseudomonas aeruginosa, triggers cell death in well-established J774 macrophages-a transformed cell line from murine reticulum cell sarcoma (Ralph and Nakoinz, 1975) . In vitro studies revealed a direct physical interaction between azurin and p53 . After internalization within J774 cells, azurin forms a complex with the tumor suppressor protein p53, stabilizes it, and enhances its intracellular level, thereby inducing apoptosis via caspase-mediated mitochondrial pathways (Yamada et al., 2002a) .
The role of azurin as a potent inducer of apoptosis in transformed macrophages prompted us to examine if azurin might have such an effect in human cancer cells. We have observed that azurin could trigger cell death in some cancer cells, such as melanoma (Yamada et al., 2002b) . Apoptosis is an essential process in cellular development and in maintaining cellular homeostasis; the failure of damaged cells to undergo apoptosis contributes to cancer progression by allowing the DNA-damaged cells to persist. In the mitochondrial apoptotic pathway, its activation depends on mitochondrial membrane disruption and the release of cytochrome c. Once activated, caspase-9 and caspase-7/3 have been shown to act on mitochondria to further disrupt their integrity, thus creating a selfamplifying feedback loop (Chandler et al., 1998; Tong et al., 2002) . However, MCF-7 human breast cancer cells lack caspase-3, a crucial component of apoptosis, but they remain responsive to many apoptotic stimuli (Le et al., 2001; Liang et al., 2001; Cuvillier et al., 2001; Hu et al., 2002; McGee et al., 2002) . Therefore, in the present study, we first investigated how azurin exerts its effect on certain molecular markers of apoptosis in breast cancer cells with differing p53 statuses and then studied its effect on breast cancer growth in an athymic mouse xenograft model.
Results

Effect of azurin treatment on the growth of various breast cancer cell lines with different p53 status
The treatment of various breast cancer cell lines with 3.5-64 mM of azurin for 24 h resulted in the inhibition of cell proliferation in a dose-and time-dependent manner. The IC 50 dose for MCF-7 (p53 þ / þ ) cells was 32 mM after 24 h of treatment with azurin-a dose far less than that for p53 null, MDA-MB-157 cells (53 mM) ( Figure 1a) . Azurin had little effect on MDD2 (containing a dominant-negative p53 variant) and MDA-MB-231 (mutant p53) cells. Approximately 29% of MCF-7 cells survived after being treated with 53 mM of azurin for 72 h (data not shown). The inhibition of cell proliferation could have been the result of apoptosis, cell cycle growth arrest, inhibition of growth, or a combination of these. We therefore next investigated whether azurin induces apoptosis in breast cancer cells.
Induction of apoptosis by azurin
In order to delineate the mechanism of action involved in azurin-induced apoptosis in breast cancer cells, a panel of breast cancer cell lines was treated with azurin and the level of apoptosis was determined with annexin V staining. The data in Figure 1b and c reveal extensive heterogeneity in the extent of apoptosis induction in the panel of cell lines. Further studies were carried out with the three representative cell lines: MCF-7 (wild-type p53), MDA-MB-157 (p53 null), and MDA-MB-231 (mutant p53). The least azurin-sensitive cell line, MDA-MB-231, displayed an increase in apoptosis of less than 15%, while the intermediately sensitive MDA-MB-157 showed an increase of 18%. MCF-7 cells exhibited a more than 50% increase in apoptosis. Analysis of the staining pattern indicated that the predominant cause of Azurin in the treatment of breast cancer V Punj et al cell death in MCF-7 was apoptosis rather then necrosis. A similar mechanism was also present in MDA-MB-157 cells, albeit to a much lesser extent ( Figure 1c ).
Effect of azurin on p53 expression
As azurin-induced apoptosis predominantly occurred in MCF-7 cells, we examined the effect of azurin treatment on p53 expression in the MCF-7, MDA-MB-157, and MDA-MB-231 cell lines. In MCF-7 cells treated with azurin, p53 expression reached its maximum 24 h after treatment, while it underwent no change in MDA-MB-157 cells (p53 null) and was variably downregulated in MDA-MB-231 cells (Figure 2a ). We then used Western blotting to examine the subcellular distribution of p53 in the cytosol, nuclear, and mitochondrial extracts from MCF-7 cells after azurin treatment for various intervals. The level of p53 increased substantially in cytosol and nuclear extracts after 8-24 h of treatment ( Figure 2b ). A portion of p53 was also translocated to the mitochondria, especially after 24 h of treatment. Such translocation of p53 to the mitochondria has been shown to be specific to p53-dependent apoptosis (Marchenko et al., 2000; Mihara et al., 2003) .
Effect of azurin treatment on the expression of pro-and antiapoptotic markers 
Caspase involvement in azurin-induced apoptosis of MCF-7 cells
Since MCF-7 cells lack caspase-3 owing to the functional deletion in the casp 3 gene (Janicke et al., 1998) , we analysed the activation of executor caspase-7 in azurin-treated MCF-7 cells. Significant levels of caspase-7 processing occurred 8-24 h after treatment with azurin, while there was little such activity in untreated cells (Figure 4a ). These results were confirmed by in situ caspase-7 processing in azurin-treated MCF-7 cells ( Figure 4b ). By 24 h, some active caspase-7 staining was even observed in the nucleus, suggesting that caspase-7 is redistributed as the apoptotic events progress. Chemotherapy-induced apoptosis by the mitochondrial pathway typically involves caspase-9 activation. Caspase-9 activation was determined by Western blotting. As shown in Figure 4c , treatment of MCF-7 cells with azurin leads to cleavage of procaspase-9 to active caspase-9 within 8 h after treatment, and this increased substantially by 24 h after treatment (Figure 4b, inset) .
The effect of azurin treatment on nuclear DNA damage was investigated by quantitative single-cell gel electrophoresis assay (comet assay). MCF-7 cells treated with azurin (50 mM) for 24 h showed a significant increase in DNA damage (exhibited by many comets) compared to the inherent DNA damage found in untreated cells. These DNA breaks could be reversed to a significant level by pretreatment of MCF-7 cells with 100 mM caspase-7 inhibitor (Z-DEVD-FMK, Calbiochem, La Jolla, CA, USA) ( Figure 4d ). The DNA damage in azurin-treated cells was significantly different (F ¼ 763.67, Pp0.0001) from that in untreated cells or cells treated with azurin in the presence of the caspase-7 inhibitor ( Figure 4e ). In azurin-treated cells, the DNA breaks were quite extensive, as evidenced by large comet trails (Figure 4d ), further supporting the hypothesis that azurin-induced apoptosis involves caspase activation.
Protein-protein interaction of azurin-p53 and its role in nuclear transport
A significant mitochondrial and nuclear accumulation of azurin was observed in MCF-7 cells between 12 and 24 h of azurin treatment (Figure 5a ). However, in the p53-negative mutant cell line (MDA-MB-157), Western blotting revealed that the bulk of azurin was retained in the cytosol (Figure 5a ), suggesting a possible role of p53 in the nuclear transport of azurin.
A GST pull-down assay was used to see if there is a direct interaction between azurin and p53. We used a GST-fused full-length p53 construct or GST constructs containing various nonoverlapping domains of p53, including the N-terminal, Middle region, and C-terminal domains. The GST-associated proteins were pulled down using glutathione sepharose beads, subjected to SDS-PAGE analysis, and then immunoblotted with antiazurin antibody. GST-p53 or the constructs with truncated p53 versions (but not GST or azurin alone) showed coelution of azurin, demonstrating a direct interaction between p53 and azurin. Moreover, azurin was shown to bind preferentially to the N-terminal and Central domain of p53 but weakly to the C-terminal of p53 (Figure 5b ). The results of these in vitro studies suggest that p53 forms a complex with azurin and perhaps helps in transporting it to the nucleus while azurin, in turn, stabilizes p53. Further studies are in progress to understand the mechanism of regulation of p53 stability by azurin in both cell and cell-free systems. To determine if azurin's complex formation with p53, which has a nuclear import/export signal, allows trafficking of azurin to the nucleus, we microinjected Alexa fluor 568 (fluorescing red) azurin to the cytosol of both MCF-7 (p53 þ / þ ) cells and MDA-MB-157 (p53À/À) cells. In MCF-7 cells, azurin remained localized mainly in the cytosol after 20 min and was still there 2 h after microinjection. However, by 4 h, azurin appeared in the nucleus, showing oligosomal DNA condensation suggesting the onset of apoptosis (Figure 5c ). In contrast, in MDA-MB-157 cells, azurin remained in the cytosol 4 h after microinjection ( Figure 5c ) and did not enter the nucleus even after 6 h. This suggests that perhaps p53 is important for the transport of azurin to the nucleus. The mechanism of entry of azurin in a cell remains unclear.
Azurin has less apoptotic effect in normal cells
To test whether azurin induced similar cell death in normal cells, we tested two mammary epithelial cell lines (HBL 100 and MCF-10F). After 72 h of incubation with 57 mM azurin, only 20% of MCF-10F cells and 18% of HBL100 cells were nonviable. Melanocytes from the foreskin incubated with the same dose of azurin after 72 h resulted in only 16% cell death.
Azurin induces regression of cancer growth and induces apoptosis in vivo
In order to understand the role of azurin in vivo, we used a nude mouse model with xenotransplanted MCF-7 cells. In athymic mice treated daily with 1 mg of azurin for 28 days, azurin substantially inhibited tumor growth. Univariate analysis of the data showed that the difference in tumor growth rates between azurintreated animals and control animals was significant (Figure 6a ). For instance, 22 days after the start of treatment, the mean tumor volume in treated mice was only 22% of the mean tumor volume for the control mice (i.e. 0.0267 and 0.1240 cm 3 , respectively, P ¼ 0.0179, Kruskal-Wallis test). When the experiment concluded on the 29th day, the mean tumor volume in the azurin-treated group was only 15% of the mean tumor volume of the control group, an 85% reduction in tumor volume. This is further illustrated by the graph of the mean tumor volumes expressed in cm 3 for the two groups over time (Figure 6b ). In the multivariate approach, nonlinear mixed-effects models were fitted to the data. The model for tumor growth over time was taken to be exponential with coefficients that were subject-specific mixed effects. For the control group, the fitted model was: tumor volume ¼ exp{À4.23 þ 0.06*time}, while for the treated group it was: tumor volume ¼ exp{À4.23 þ 0.03*time}. The difference was statistically significant (P ¼ 0.0456). Taken together, these in vivo data suggest that when azurin is administered systemically, it exerts a significant inhibitory influence on the growth and progression of MCF-7 tumor xenotransplants.
During 28 days of treatment, the treated animals did not show any sign of toxicity such as weight loss or other commonly observed signs of toxicity. Furthermore, following necropsy, all viscera were histologically examined, and no discernable alterations were noted when comparing the viscera of azurin-treated animals to those of controls.
Both control and azurin-treated tumors were morphologically examined. In a routine H&E stain, control tumor parenchyma was intact, with large numbers of dividing cells with mitotic figures (Figure 7a ), suggesting an aggressive phenotype. In azurin-treated animals, tumor parenchyma was characterized by scattered areas of disintegration and increased intercellular spaces associated with a remarkable lack of mitotic figures (Figure 7b ). The rate of tumor cell proliferation between the control and azurin-treated animals was estimated by Ki-67 antibody staining. In the control group, the tumors showed numerous proliferating cells (Figure 7c) , whereas in the azurin-treated group a sharp reduction was seen in the number of proliferating cells (Figure 7d ). The extent of apoptosis in tumors, as estimated by TUNEL stain, showed a marked increase in apoptotic figures in the azurin-treated group (Figure 7f ) rather than in the controls, where apoptotic cells were rarely encountered (Figures 7e).
For caspase expression in vivo, we relied mostly on immunohistochemistry (Cowan et al., 2001) in our xenotransplant experiments. We first confirmed by TUNEL assay that the regression of tumors was due to apoptosis. In such azurin-treated tumors, we observed a higher level of caspase-9 staining as compared to control tumors (data not shown). In control tumors, caspase-7 was expressed in a few cells (Figure 7g ). However, in azurin-treated animals the expression of 
Discussion
Several contemporary reports have shown that microbial pathogens replicate at tumor sites under hypoxic conditions and stimulate the host immune response, leading to the inhibition of tumor growth (Alexandroff et al., 1999; Jain and Forbes, 2001; Chakrabarty, 2003) . In addition to bacterial pathogens, other infectious agents such as Toxoplasma gondii or Besnoitia jellsoni are known to activate macrophages and induce tumor regression, presumably through the elaboration of antiangiogenic agents (Hunter et al., 2001) . Unfortunately, the use of live microorganisms is always associated with their infectious characteristics and other side effects. As a result of our pursuit to identify a constituent of a cell or its metabolite that may have anticancer activity and can reduce the side effects associated with microorganisms, we have identified, isolated, and purified a bacterial cupredoxin, azurin, that has the potential of regressing tumor growth in vitro and in vivo in nude mice. Azurin is a member of a family of low-molecularweight, soluble, copper-containing proteins called cupredoxins. While a great deal is known about cupredoxins' electron transfer mechanisms, and X-ray been recently proposed that in response to certain noxious stimuli, both mammalian cells and present day bacteria secrete redox proteins, which in turn induces the cell death. ).
Azurin exerts a high level of cytotoxicity towards MCF-7 cancer cells. The ability of azurin to form a complex with p53-thereby allowing its stabilization and consequent high intracellular level in MCF-7 cells-appears to indicate that a p53-dependent mechanism might be the major mode of action of azurin-induced apoptosis in MCF-7 cells. A lack of p53 in MDA-MB-157 cells or the presence of nonfunctional p53 in MDD2 and MDA-MB-231 cells supports this notion since there is a comparative loss of azurin's cytotoxicity towards these cells.
The intriguing question is to what extent azurininduced apoptosis in MCF-7 cells is based on the intracellular stabilization of p53. p53 is not only able to upregulate transcriptionally particular proapoptotic genes such as Bax, peg3, Apaf-1, caspase-9, and PUMA but also to repress some antiapoptotic genes like Bcl-2 (Gross et al., 1998; Budhram-Mahadeo et al., 1999 ). An increase in the level of p53 can regulate and promote discrete steps of the apoptosis cascade such as upregulation of Bax levels, triggering of Bax translocation to mitochondria, release of cytochrome c from mitochondria, activation of apoptosome, etc. We report here that MCF-7 cells containing wild-type p53 were far more sensitive to azurin at all dose levels than were: MDA-MB-157 cells, a p53-negative cell line; MDA-MB-231 cells that contain mutant p53 (codon 280, Arg to Lys) in exon 8 (Runnebaum et al., 1994) ; or MDD2 cells with a dominant-negative p53. The expression of p53 increased only in MCF-7 cells. Therefore, functional p53 was required for an effective apoptotic pathway in these cells. Bax translocation from the cytosol to mitochondria (Figure 3c ) is a classical event in the mitochondrial apoptotic pathway and has been reported to occur in many cell lines in response to various apoptotic stimuli (Gross et al., 1999; Mooney et al., 2002) . Bax and Bcl2 play a major role in determining whether cells will undergo apoptosis under experimental conditions. A ratio of Bax to Bcl2-rather than antiapoptotic Bcl2 alone-is important in cell survival or apoptotic death in response to death stimuli (Salomons et al., 1997) . The average ratio of Bax:Bcl2 in p53-containing MCF-7 cells treated with azurin was higher than in the untreated control, while in p53-defective cells this ratio remained lower over the untreated control. The low level of cell death in MDA-MB-157 cells could result from the Bcl2-insensitive apoptotic p53-independent pathway (Strasser et al., 2000) . Nonetheless, our results showed that functional p53 is important in the p53-dependent pathway leading to apoptosis. However, the possibility of p53-independent cell death in response to azurin treatment might also exist. The results obtained with cells having nonfunctional p53 or no p53 appear to show that the presence of wild-type p53 amplifies the death signal in response to azurin treatment. Furthermore, using GST pull-down assay, we have demonstrated that azurin is capable of directly binding to p53. Apparently, the protein-protein interaction involved some of the residues beyond the N-terminal: azurin also displayed interaction with the M-terminal. However, there was only a weak interaction between azurin and the C-terminal of p53.
MCF-7 cells are relatively resistant to apoptosis induced by many stimuli because of their loss of functional casp 3 resulting from the deletion of 47 base pair within exon 3 of the caspase 3 gene (Janicke et al., 1998) . Caspase-7 is related to caspase-3 and shows the same synthetic substrate specificity in vitro (Talanian et al., 1997) , suggesting that caspase-3 and -7 have possibly overlapping roles in apoptosis (Woo et al., 1998) . Caspase-7 can cleave PARP (poly-ADP ribose Polymerase) and DNA fragmentation factor (DFF), which can lead to DNA fragmentation (Enari et al., 1998; Hu et al., 2001; Wojciechowski et al., 2003) . It appears that azurin treatment of MCF-7 cells, within 8-24 h, signals the mitochondrial pathway to recruit and activate caspase-9. Caspase-9 then activates caspase-7, which in turn puts into motion a chain reaction that results in apoptotic cell death. Caspase-7 is thought to play the functional role of executor caspase in MCF-7 cells in response to various apoptotic stimuli (Oberhammer et al., 1993; Heerdt et al., 1999; Hishikawa et al., 1999; Zhivotovsky et al., 1999; Liang et al., 2001; Mooney et al., 2002; Lee et al., 2003; Onuki et al., 2003) . Moreover, Bax-mediated apoptosis has also been reported to be independent of caspase-3 deficiencies and reconstitution of caspase-3 does not alter overall cell death (Marcelli et al., 1998; Kagawa et al., 2001; Wojciechowski et al., 2003) .
Studies using etoposide, doxorubicin, Cisplatin, and key adjuvant drugs for breast cancer treatment concluded that MCF-7 cells were sensitized to apoptosis only when these cells were reconstituted with caspase-3 (Blanc et al., 2000) . Our studies have shown that the intrinsic mechanism of apoptosis is functional in MCF-7 cells but is dependent on external stimuli. Azurin can evoke an alternate apoptotic pathway independent of caspase-3, making it a promising agent for combination chemotherapy that merits further study.
Altogether, the most likely sequence of events responsible for azurin-induced apoptosis in MCF-7 cells includes a decrease in Bcl2 level and an increase in the mitochondrial membrane potential with a consequent release of cytochrome c. The released cytochrome c interacts with Apaf-1, dATP (or ATP), and procaspase-9, leading to the activation of caspase-9, which, in turn, activates caspase-7 and eventually induces apoptosis.
Systemic administration of azurin in MCF-7 xenotransplanted nude mice confirmed azurin's inhibitory effect on breast cancer. Throughout 4 weeks of azurin treatment, there was a dramatic inhibition on tumor growth, and tumor weight had decreased by the end of the experiment. All animals tolerated azurin treatment very well, with no occurrence of any significant differences in body weight between treated and control animals. Based on our results, azurin might prove to be a novel, nontoxic, water-soluble chemotherapeutic agent for human breast cancer. The clinical significance of these findings-including the efficacy of truncated versions of this redox protein in order to develop a peptide-based anticancer agent (Torchilin and Lukyanov, 2003)-is being investigated.
Materials and methods
Cell lines and reagents
The human breast cancer cell lines MCF-7 (p53 þ / þ ), MDA-MB-157 (p53À/À), MDD2 (MCF-7 cell line containing dominant-negative p53), and MDA-MB-231 (mutant p53)-along with the normal breast cells (MCF-10F) and foreskin cells-are all from the stock culture collection of the Department of Surgical Oncology, University of Illinois at Chicago (UIC), Chicago. HBL100 cells were a gift from Dr Nita J Mahile, Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota.
The cells were grown either in MEM medium supplemented with Earle's salt, 10% FBS and Penicillin/Streptomycin, Macoy's 5A medium, or in RPMI 1640 supplemented with penicillin/streptomycin and FBS. All cells were grown at 371C in 6% CO 2 .
Plasmid constructs
Dr R Baskaran, University of Pittsburgh Medical Center, Pittsburgh, and Dr Thomas Shank, Princeton University, Princeton, kindly provided the various p53-GST constructs used in the present study.
Preparation of azurin
The azurin-encoding gene of P. aeruginosa was amplified and cloned in pUC19. Azurin was purified from E. coli JM109 as described previously (Yamada et al., 2002a) .
Cell proliferation assay
Cell proliferation was analysed by Cell Titer 96 AQ ueous One Solution Cell Proliferation Assay Kit (Promega, Madison, WI, USA) following the manufacturer's instructions, and as detailed elsewhere (Eilon et al., 2000) . Data were calculated as a percentage of untreated control cells.
Annexin-V-FITC assay
Cells (10 5 ) were treated with azurin for 4, 8, 12, and 24 h. Detached and adherent cells were pooled, washed with PBS, and resuspended in binding buffer (BD Biosciences). Cells were then stained with annexin-V-FITC antibody as recommended by the manufacturer. Propidium iodide (PI) (final concentration 1 mg/ml) was added immediately prior to analysis by Flow Cytometry. Bivariant analysis of FITC fluorescence and PI fluorescence gave different cell populations, where FITC(À) and PI(À) were designated as viable cells, FITC( þ ) and PI(À) as apoptotic cells, and FITC( þ ) and PI( þ ) as late apoptotic or necrotic cells.
Protein extraction and Western blot analysis
The breast cancer cells were plated and cultured in a complete medium and treated with azurin (53 mM) for various time intervals. The cells were then washed and detached with trypsin-EDTA. Cells were collected by centrifugation and disrupted in lysis buffer (25 mM Tris-HCl (pH 8), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 100 mM DTT, and supplemented with protease cocktail inhibitor) for 30 min (Asher et al., 2001) . Cytosolic and mitochondrial fractions were prepared as described by Deveraux et al. (1999) . The nuclear extracts were separated following the procedure of Raffo et al. (2000) . For detection of caspase-7 and 9, the treated cells were lysed in lysis buffer containing 20 mM sodium phosphate (pH 7.4), 150 mM NaCl, 0.1% Triton X-100, and 10% glycerol supplemented with a protease inhibitor cocktail tablet. The caspase-9 antibody used here recognizes both cleaved and full-length caspase-9.
Protein contents were determined using modified BioRad Dc assay reagent. In total, 40-60 mg of protein was separated on SDS-PAGE and electrophoretically transferred onto a nitrocellulose membrane. Membranes were then blocked with 1% Western blocking reagent (Roche Biochemicals, Mannheim, Germany) and probed with primary antibody followed by washing in TBS-T (Tris buffered saline with Tween 20). Washed membranes were then probed with the corresponding secondary antibody. After washing, the membranes were treated with enhanced chemiluminescence reagents (Amersham Pharmacia, Piscataway). The specific protein bands were visualized by autoradiography. b-Actin was used as a loading control. The various antibodies used in immunoblotting include p53 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bax, Bcl2, cytochrome c (BD Biosciences, San Jose, CA, USA), caspase-7 and caspase-9 (Cell Signaling, Beverly, MA, USA), Cytochrome c oxidase (Molecular Probes, Eugene, OR, USA), and b-actin (Sigma chemicals, St Louis).
Densitometry analysis
Western blots were scanned and analysed using Image Quant version 1.2 software on a Macintosh computer. The bidimensional optical densities were quantified and the relative ratio of the various proteins was calculated.
GST pull down assay
GST-FLp53 (GST fused full-length p53) and the various truncated versions of p53, GST-N-p53 (GST fused N-terminal domain of p53), GST-M-p53 (GST fused Central domain of p53), and GST-C-p53 (GST fused C-terminal domain of p53) were prepared after induction with IPTG and purified using a standard protocol as recommended by the manufacturer (Amersham Pharmacia Biotechnology, Piscataway). Equal amounts of GST-tagged p53 or GST alone and azurin were mixed, and the putative complex was pulled down using Glutathione Sepharose 4B beads. The beads were washed with excess of PBS to remove unbound proteins. As controls, GST, GST-p53, and azurin alone were individually treated using the same procedure as above. Proteins were then subjected to SDS-PAGE and transferred onto a PVDF membrane (0.2 mm, BioRad, Hercules), which was probed with antiazurin and p53/ GST antibodies.
Enzyme-linked immunosorbent assay for caspase-7
An ELISA was standardized to detect specifically in vitro endogenous levels of active caspase-7 in the azurin-treated MCF-7 cells over various time intervals using the Quantikine human active caspase-7 immunoassay kit (R&D system, Minneapolis, MN, USA). This procedure specifically detects the cleaved caspase-7, and does not crossreact with procaspase-7. The amount of caspase-7 was calculated from a standard curve, and the results are presented as relative amounts of active caspase-7 as described by Saunders et al. (2000) . An in situ immunodetection of active caspase-7 was carried out using confocal laser microscopy. In order to study intracellular localization of caspase-7, the procedure of Meller et al. (2002) was used with some modifications. Briefly, cells were grown in 0.17 mm delta T dishes (Bioptech, Butler, PA, USA) and treated with azurin for various time intervals as indicated. The cells were washed with PBS and fixed with 3% paraformaldehyde. The fixed cells were permeabilized with 0.1% Triton X-100 in PBS for 15 min. Nonspecific binding sites were blocked with 5% donkey serum (Jackson Immuno Research, West Grove, PA, USA) for 1 h followed by overnight incubation with the primary antibody (cleaved caspase-7; Asp198 antibody; Cell Signaling) in 0.1% BSA in PBS. Cells were washed with PBS before incubating with Cy2-conjugated donkey anti-rabbit IgG secondary antibody for 1 h. After washing the cells with PBS, the nucleus was stained blue with DAPI. Finally, the cells were covered with a thin film of Prolong Antifade reagent (Molecular Probes, Eugene, OR, USA), and images were taken under a confocal microscope. The presence of active caspase-7 is indicated by green fluorescence because of Cy2-conjugated secondary antibody.
Microinjection of azurin in MCF-7 and MDA-MB-157 cells
Microinjection was performed following the basic protocol as described by Gajate et al. (2000) . Briefly, MCF-7 and MDA-MB-157 cells were cultured overnight on 14-mm glass coverslips coated with poly-D-lysine and adhered to a 35-mm tissue culture dish (Mat Tex Corporation, Ashland, MA, USA). Azurin was chemically labeled (red) with Alexa Fluor 568 (Molecular Probes, Eugene, OR, USA) as recommended by the manufacturer. The labeled azurin was microinjected into the cytoplasm of single cells using a computer-controlled microinjector (AIS 2) system. All microinjection experiments were performed using a 0.5 s injection time and 100 hPa pressure with a Zeiss 200 M microscope. Approximately 75-100 cells were injected in each dish. After microinjection, cells were further incubated at 371C in 6% CO 2 for varying time intervals. Cells were then fixed with 4% paraformaldehyde, nuclear DNA was stained blue with DAPI, and fluorescent images were acquired with a Zeiss LSM 510 confocal laser microscope and analysed with CLSM software.
Comet assay
The single-cell gel electrophoresis was carried out according to the procedure of the manufacturer with minor modifications (Trevigen, Gaithersburg, MD, USA) as described previously (Salti et al., 2000) . Slides were dried in 80% ethanol, stained with SYBR Green (Trevigen, Gaithersburg, MD, USA), and viewed under a fluorescent microscope emitting light between 425 and 500 nm. The cells were qualitatively scored from 0 to 4 according to the size of the comet tail. Cells with a score of zero had intact DNA and cells with a score of four were significantly damaged. The cells were scored according to the equation:
where n 0 is the number of cells with a score of 0, n 1 is the number of cells with a score of 1, etc., and N is the total number of cells counted. Duplicate samples were prepared for each treatment, and 400 cells were scored for each sample.
In vivo xenotransplant studies MCF-7 cells (5 Â 10 5 ) were injected into the lowest right mammary fat pad of estradiol-pretreated female nude mice.
The mice were randomly split into two groups of 10 mice each. The treated group received 1 mg of azurin in 1 ml of normal saline intraperitoneally daily for 28 days, and the control group received 1 ml of saline i.p. daily for 28 days. The treatment started three days after MCF-7 inoculation. On the 29th day, all of the animals were killed and a detailed necropsy was performed. All of the tumors and viscera were preserved for histological and immunocytochemical examination. During the course of the experiment, the mice were examined daily, and 3-axis tumor volume and body weights were measured twice weekly.
Immunohistological methods
Cell proliferation in tumors was evaluated by Ki-67 antibody (U0028, Epos, Dako Co., Denmark). Slides were deparaffinized, heated in a microwave oven for 15 min in citric buffer (0.01%), and covered with antibody for 1 h. The antibody is HPR-conjugated; therefore, after 2 Â PBS wash, the slides were stained with DBA and counterstained with hematoxylin for characterization of tumor morphology. Apoptotic cells were evaluated by the TUNEL assay as recommended by the ApopTag in situ hybridization detection kit (Oncor, Gaithersburg, MD, USA). The top section on each slide, which was incubated without digoxigenin-dUTP, was used as a negative control. Tissue sections were counterstained with methyl green for visualization of tumor morphology. The expression of caspase-7 was examined by immunohistochemistry on formalin-fixed, paraffin-embedded tumor samples. Tissue sections were treated with a retrieval solution (citric buffer, 0.01%) to increase the intensity of the reaction product. Polyclonal rabbit antibodies from NeoMarker (Fremont, CA, USA) were used at concentrations of 1 : 200, 1 : 100, 1 : 100, and 1 : 200, respectively. The slides were covered with the corresponding antibody overnight. The ABC kit and DBA staining were employed for the amplification of the signal and the visualization of the antigen. The top section of each slide was used as a control and was not treated with the corresponding antibody. The slides were counterstained with hematoxylin.
Statistical methods
Both univariate and multivariate methods were used. The univariate method consisted of computing the summary statistics for the tumor volume for each group (treated with azurin and control) for each of the 10 days on which measurements were taken. The nonparametric Kruskal-Wallis test was used to examine the differences between the groups at each time point, and P-values were computed to determine the significance of the treatment.
In the multivariate approach, analysis was based on 19 animals (10 treated mice and nine control mice). Exponential models were fitted to the data in order to study the growth of the tumor over time, measured as days from the injection of cancer cells. Analysis was carried out by SAS s . For IC50 determination from cell proliferation assay, nonlinear regression analysis was performed with Microsoft Excel to generate curves for the calculation of IC 50 (He et al., 2003) .
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